Rhode Island College

Digital Commons @ RIC
Master's Theses, Dissertations, Graduate
Research and Major Papers Overview

Master's Theses, Dissertations, Graduate
Research and Major Papers

11-29-2018

Haloperidol and Postoperative Nausea and Vomiting: A
Systematic Review
Megan Collins

Follow this and additional works at: https://digitalcommons.ric.edu/etd
Part of the Perioperative, Operating Room and Surgical Nursing Commons

Recommended Citation
Collins, Megan, "Haloperidol and Postoperative Nausea and Vomiting: A Systematic Review" (2018).
Master's Theses, Dissertations, Graduate Research and Major Papers Overview. 288.
https://digitalcommons.ric.edu/etd/288

This Major Paper is brought to you for free and open access by the Master's Theses, Dissertations, Graduate
Research and Major Papers at Digital Commons @ RIC. It has been accepted for inclusion in Master's Theses,
Dissertations, Graduate Research and Major Papers Overview by an authorized administrator of Digital Commons
@ RIC. For more information, please contact digitalcommons@ric.edu.

HALOPERIDOL AND
POSTOPERATIVE NAUSEA AND VOMITING:
A SYSTEMATIC REVIEW

by

Megan Collins
A Major Paper Submitted in Partial Fulfillment
of the Requirements for the Degree of
Master of Science in Nursing
in
The School of Nursing
Rhode Island College
2017

Abstract
Postoperative nausea and vomiting (PONV) is a complication that affects up to 30% of
the patients undergoing general surgery. This complication can be dangerous for patients,
increase recovery time and decrease patient satisfaction scores. There are many different
medications that have been used to prophylactically treat PONV including haloperidol. A
systematic review was conducted to determine the efficacy of haloperidol as an
antiemetic. Databases were searched and inclusion and exclusion criteria were applied to
finalize the articles included. The PRISMA framework was used to guide the review and
a total of five studies were critically analyzed. Two data collection tables were created for
each article, one that illustrated the design of the study and one that illustrated the results.
The CASP checklist was utilized to critically appraise each article. Finally, a cross study
analysis was conducted to compare the studies. Haloperidol was studied alone and in
combination with other antiemetic medications. Overall, these studies showed a decrease
in PONV in patients medicated with haloperidol. Using haloperidol prophylactically,
especially when utilized with multiple medications, decreased episodes of vomiting and
levels of nausea. Haloperidol can be a useful and safe medication that anesthesia
providers may utilize to prevent PONV. Further research is needed to study the impact on
general surgery procedures and with larger samples.
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Haloperidol and Postoperative Nausea and Vomiting: A Systematic Review
Background/Statement of the Problem
Post-operative nausea and vomiting (PONV) has been a continuous problem for
patients recovering from surgery. Postoperative nausea and vomiting is defined as any
nausea, retching, or vomiting in the 24 period after surgery (Flood, Rathmell, & Shafer,
2015). In 1914, the first journal of anesthesia published an article about prophylactically
treating PONV. Even though it has been a source of conversation since then, it remains
one of the most common complications of general anesthesia (Nagelhout & Plaus, 2014).
Incidence as high as 30% in all patients and as high as 80% in cases where the patient
was at high risk for PONV are reported (Pierre & Whelan, 2013).
This common complication often increases recovery time, which may lead to an
unexpected hospital stay or increased length of stay after the procedure (Flood et al.,
2015). Vomiting or retching after surgery can be dangerous for the patient and cause
further complications such as suture dehiscence and aspiration (Nagelhout & Plaus,
2014). Postoperative nausea and vomiting is very uncomfortable for the patient and
contributes to dissatisfaction scores for anesthesia providers (Flood et al., 2015). Patients
have even ranked PONV as the most important clinical anesthesia complication to avoid,
putting it ahead of other complications such as pain, intraoperative recall and gagging on
the endotracheal tube (Flood et al).
When a patient goes under general anesthesia, there are many factors that can
contribute to PONV. These include the medications used, such as the volatile anesthetics
and opioids, as well as other factors such as the patient’s anxiety, motion and surgical
manipulation (Pierre & Whelan, 2013). Volatile anesthetics have been shown to increase
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PONV two-fold and nitrous oxide has also been shown to have an increased risk. Adding
opioids throughout the case can increase PONV in a dose-dependent manner (Pierre &
Whelan). All of these combined provide an environment where PONV can easily occur.
There are identified risk factors that place patients are increased risk for PONV.
These risks are divided into patient specific, anesthesia related, and surgery related
(Nagelhout & Plaus, 2014). Patient specific risk factors include female gender, age less
than 50, nonsmokers, history of PONV and history of motion sickness. Anesthetic related
factors include use of volatile anesthetics, use of nitrous oxide and
intraoperative/postoperative use of opioids. Surgery related risk factors include the
duration of the surgery being more than one hour and the type of surgery. Laparoscopic
surgery has been identified as one of the surgical procedures with a high incidence of
PONV (Nagelhout & Plaus). When a patient has several risk factors, it can increase the
risk of PONV up to 80% (Pierre & Whelan, 2013).
To prevent the patient from having to experience PONV, a prophylactic approach
has been used. To prophylactically treat a patient, especially one who has been
determined as high risk, a multimodal approach works well due to the complexity of
activating the vomiting center (Pierre & Whelan, 2013). Postoperative nausea and
vomiting is controlled in the brain at what is called the vomiting center. This is in the
medulla oblongata and contains the nucleus of the tractus solitaries (NTS). Multiple
neurotransmitters control the activity of this vomiting center. These neurotransmitters are
dopamine, serotonin, substance P, acetylcholine, gamma-aminobutyric and cannabinoids.
PONV can also be activated through the chemoreceptor trigger zone (CRTZ) when the
body detects noxious chemicals (Flood et al., 2015). The different medications can work
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independently to prevent nausea and vomiting, but when used in combination they also
have additive effects (Pierre & Whelan, 2013).
One of these medications is haloperidol, which is a butyrophenone, and has an
antagonistic effect on the D2 dopamine receptors. Haloperidol is primarily used to treat
schizophrenia and other psychiatric disorders but has other uses, such as a treatment for
intractable hiccups. It also has antiemetic properties (Flood et al., 2015). Haloperidol
does have side effects, especially at higher doses, such as cardiac arrhythmias,
prolongation of the QTc interval, sedation, and extrapyramidal symptoms. These side
effects provide some risk with using haloperidol as a prophylactic medication (Pierre &
Whelan, 2013).
The purpose of this systematic review is to review current evidence of how
haloperidol effects postoperative nausea and vomiting in patients who have undergone a
laparoscopic surgical procedure.
Next, a review of the literature will be presented.
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Literature Review
A review of the literature was conducted to examine information about PONV
and the effects of haloperidol. Databases searched were PubMed, CINAHL, Medline, and
google scholar. Search words included postoperative nausea and vomiting, treatment,
causes, risk factors, haloperidol and laparoscopic surgery. Evidence-based reviews,
randomized control trials, guidelines, quasi-experimental studies, and non-experimental
studies were included in this literature review.
Laparoscopic Surgical Procedures
Laparoscopic surgery has greatly changed the way general, gynecological and
urological surgery is done. The laparoscopic cholecystectomy is not only the most
common laparoscopic surgical procedure performed, it is also now considered the gold
standard for removing the gallbladder (Chamberlain & Sakpal, 2009). A laparoscopic
surgical procedure is considered a minimally invasive surgical procedure (Nagelhout &
Plaus, 2014). This allows a surgeon to perform a surgical procedure with less blood loss,
decreased pain, and a quicker recovery for the patients. Although laparoscopic technique
has been changing clinical practice for approximately 30 years, it was first used in 1901
for an endoscopic examination of the peritoneal cavity by a German surgeon. For 70
years after that surgery, there were surgeons who attempted to use a laparoscopic method.
However, there were many complications during those times such as cautery injuries and
perforations. As technology advanced, especially with videoscopic imaging being
developed in the 1980’s, the first laparoscopic cholecystectomy was performed with
video assistance by a French surgeon in 1988. With this successful procedure, the health
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care community began to pay attention to utilizing laparoscopic procedures (Nagelhout &
Plaus).
Now that these procedures can be done with video assistance, there are many
advantages to them. Laparoscopic surgeries tend to be safer, less painful, minimally
invasive and have a faster recovery time to normal function (Nagelhout & Plaus, 2014).
These procedures are usually associated with less blood loss, fewer blood transfusions,
and less postoperative opioid requirements (Butterworth, Mackey & Wasnick, 2013).
Although there are many benefits to laparoscopic surgical procedures, they are
also complex and do have their own complications (Nagelhout & Plaus, 2014). To
perform a laparoscopic procedure, the surgeon creates a pneumoperitoneum where air or
gas is instilled into the peritoneal cavity under pressure. This creates an area where the
surgeon can visualize the field they are working on. The creation of this
pneumoperitoneum is responsible for most of the complications seen with laparoscopic
surgical procedures, including vascular or bowel injury and hemodynamic changes.
These can be seen intraoperatively as well as postoperatively (Nagelhout & Plaus). The
other complication frequently seen with laparoscopic procedure is increased incidence of
nausea and vomiting which is believed to be from the increased air or gas in the
peritoneal cavity causing irritation (LiveStrong, 2015). Combining this irritation with
other risk factors for PONV, such as anesthetic gases or opioids, creates a greater
occurrence of PONV (LiveStrong).
Postoperative Nausea and Vomiting
Postoperative nausea and vomiting is one of the most common postoperative
complications seen. It is defined as any nausea, retching, or vomiting occurring during
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the first 24 hours after surgery (Pierre & Whelan, 2013). It is seen in 30% of patients
undergoing general anesthesia, and up to 80% of patients who have been identified as
high risk patients (Pierre & Whelan). Experiencing PONV can lead to prolonged
recovery, unplanned or prolonged hospital admissions, poor satisfaction scores, and
higher patient cost (Smith, H., Smith, E., & Smith, B., 2012). This common complication
is disliked by patients so intense that one study showed that patients ranked vomiting as
more undesirable than gagging on the tracheal tube, incisional pain, recall, residual
weakness, shivering, sore throat, and somnolence. Patients stated they were even willing
to pay between $56-100 for hypothetical effective antiemetic prophylaxis (Smith et al.).
Also, it puts the patient at risk for further complications such as aspiration pneumonia,
Boerhaave’s syndrome, subcutaneous emphysema, pneumothorax, rupture of the trachea,
loss of vision, and suture dehiscence (Rusch, Eberhart, Wallenborn, & Kranke, 2010).
Postoperative nausea and vomiting is controlled in the body from the vomiting
center. This is an area in the medulla that receives signals and can trigger nausea and/or
vomiting. The vomiting center also communicates with the chemoreceptor trigger zone
which can trigger vomiting. These two areas have multiple receptors, which can cause
them to be activated in many different ways. The receptors found here are histamine,
serotonin, cholinergic, neurokinin-1 and D2 dopamine receptors. Due to the multiple
ways these centers can be activated, there are many different ways which a patient can be
treated for PONV (Chatterjee, Rudra & Sengupta, 2011).
It is very important to prevent PONV whenever possible so that patients do not
have to experience this complication. One study stated that while laparoscopic procedures
usually are associated with short periods of hospitalization, PONV is being seen as the
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most common reason for prolongation of hospital stay after a laparoscopic
cholecystectomy (Akkurt et al., 2009). This study compared recovery time of patients
receiving propofol for anesthesia and patients receiving a general anesthetic gas,
desflurane. There was a total of 68 patients who were included in this study. All patients
were in the ASA class I or II and had a laparoscopic cholecystectomy. Five patients were
excluded from this study, with 63 remaining who were then divided into two groups. In
the propofol group, there was a significant decrease in PONV which coincided with a
decrease in hospitalization time. Only two patients (6.7%) in the propofol group had
vomiting episodes, while 16 patients (53.3%) in the desflurane group did. This was found
to be statistically significant with P < 0.005. Also, the patient satisfaction scores were
significantly higher in the group that did not receive desflurane (P <0.001) (Akkurt et
al.).
Risk Factors for Postoperative Nausea and Vomiting and Scoring Systems
There are identified factors that can predict if a patient will be at higher risk for
developing nausea and vomiting. There are patient specific factors, anesthesia related
factors and surgery specific factors (Pierre, Benais & Pouymayou, 2002). Patient specific
risk factors include the female gender, age less than 50, nonsmokers, and a history of
PONV or motion sickness. Anesthesia related risk factors include the use of volatile
anesthetics, nitrous oxide, and opioids. Surgery related risk factors include the duration of
the surgery and the type of surgery (Nagelhout & Plaus, 2014).
There have been several different scoring systems utilized to determine a patient’s
risk level. One of these scoring systems is called the Sinclair-score (Pierre et al., 2002).
This system takes into account all three kinds of risk factors. Another scoring system is
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called the Apfel-score which examines four specific risk factors including female gender,
previous history of PONV or motion sickness, non-smoking status, and postoperative use
of opioids (Pierre et al.). Health care facilities have a protocol on which scoring systems,
if any, are used to identify high risk patients and how those patients are managed. Some
facilities lean towards a risk factor directed prophylaxis treatment, while other facilities
have a set order for patients to be prophylactically treated (Wolf et al., 2016).
In a study that compared these two scoring systems, five hundred consecutive
adult patients who were undergoing general anesthesia for a throat, thyroid, breast or
gynecological procedure were included (Pierre et al., 2002). The authors excluded
patients who had been premedicated for nausea and vomiting, which left 428 patients. Of
those patients 50% experienced PONV. It was found that the area under the receiver
operating characteristic (ROC)-curve was significantly greater for the Apfel scoring
system as compared to the Sinclair-scoring system, 0.71 vs 0.64. An area under the ROCcurve of 1.0 represents a perfect discrimination in patients. Thus, these areas under the
ROC-curve indicate that the Apfel scoring system is better at predicting the likelihood of
PONV. The Apfel scoring system is relatively simple and easy for health care workers to
use and help prevent PONV in high risk patients (Pierre et al.).
Risk Factor-Directed Prophylaxis
There are various theories about how risk factors effect prophylactically treating a
patient. Some providers believe that all patients regardless of their risk factors should be
treated liberally for PONV, while others believe that the use of any medication should be
patient specific and based on their risk factors (Wolf et al., 2016). Wolf et al. examined
the effectiveness of treating patients based on their risk factors for PONV. The study
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included 92 patients who had undergone strabismus surgery and included a mix of adult
and pediatric patients. The Apfel-scoring system was used to determine if the patient was
high risk. If the patient scored a 3-4 on the scale they were prophylactically treated with a
multimodal approach which included multiple medications that effected different
receptors. Their surgeries were done without a general anesthetic gas. Overall, 45 patients
(49%) were found to be in the high-risk category. There were 47 patients (51%) that were
put into the low-risk category. Out of all 92 participants, there were 16 (17%) who
experienced PONV. The adults that were high risk had an incidence of 8% (n = 4) of
PONV. The children who were in the high risk category had a 9% (n = 4) incidence of
PONV. Adults who were determined to be lower risk had an incident of 21% (n = 10) and
children had an incidence of 38% (n = 17). The study concluded with advocating for a
more liberal use of prophylactic medications regardless of what the patients risk score
was based on how high PONV was even in the low risk group (Wolf et al.).
An evidence-based review discussed prophylactically treating patients for PONV
based on risk factors (Rusch et al., 2010). The authors stated that PONV is a significant
problem that should be adequately prevented and treated quickly if it occurs. The highest
risk factors were identified as female gender, history of PONV or motion sickness, use of
opioids during and after surgery, use of inhalation anesthetics and nitrous oxide and the
duration of the surgery. This review focused on how risk-adapted prophylaxis compared
to a fixed prophylaxis. It was stated that exclusively using a risk-adapted method did not
provide any greater benefit than a fixed method where every patient is treated to prevent
PONV. It also stated that patients that did fall into the high-risk categories required more
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than one drug to prevent PONV and recommended that they should always be treated
with a multimodal prophylactic method (Rusch et al.).
Multimodal Prophylaxis of Postoperative Nausea and Vomiting
It has been shown that utilizing a multimodal approach to PONV can be very
effective, even in patients that are at high risk. Gan et al. (2014) presented consensus
guidelines for the management of PONV. These guidelines had eight goals: to understand
who is at risk for PONV; establish factors that reduce these risks; determine the most
effective drug therapy for prophylaxis; ascertain the best treatment for PONV, determine
the best timing and dosage of prophylactic treatment; evaluate cost-effectiveness of
management strategies; create an algorithm; and propose a research agenda for further
research in this topic.
Due to the complex nature in which PONV occurs, it can be very beneficial to
treat patients prophylactically with multiple drug classes (Gan et al., 2014). It has been
shown that patients at moderate or high risk should always be treated with a combination
of medications preoperatively and intraoperatively to prevent PONV. For example,
serotonin antagonists, such as Zofran, have stronger antiemetic effects than antinausea
effects where as dopamine antagonists, such as haloperidol, have stronger antinausea
effects (Gan et al.). It is beneficial to the patient to give these medications in combination
to get a decreased occurrence of PONV.
It has also been shown that medicating patients with two medications together,
such as dexamethasone and Zofran, has a significantly higher efficacy than when either
drug is given alone (Gan et al., 2014). In these current guidelines, the groups of
medications that are recommended for prophylactic treatment are 5-HT3 receptor
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antagonists, Nk-1 receptor antagonists, corticosteroids, butyrophenones, antihistamines,
anticholinergics, and phenothiazines. There are other medications such as propofol,
gabapentin, and versed that have also shown antiemetic and/or antinausea properties (Gan
et al.).
Chatterjee, Rudra and Sengupta (2011) stated that for patients in moderate and
high risk groups, regional anesthesia should always be considered. This would greatly
decrease the risk of PONV. However, if general anesthesia must be used the patient
should receive combination antiemetic therapy. This has been shown to be superior to
monotherapy as it allows multiple mechanisms of actions through different receptor sites
to prevent PONV (Chatterjee et al.).
The effectiveness of using multiple medications to prophylactically treat PONV
was demonstrated in a study by Biswas and Rudra (2003). This study included 120
patients who had gone under general anesthesia for a laparoscopic cholecystectomy. The
patients were divided into two groups, one group received only granisetron and the other
group received granisetron and dexamethasone, both of which medications have been
shown to decrease PONV. In the group with only the granisetron 83% (n = 50) of the
patients did not experience PONV within the first 24 hour period after surgery. In the
group with both the granisetron and the dexamethasone, 95% (n = 57) of the patients did
not experience PONV. Prophylactically treating with multiple medications that work on
different receptor sites has a greater effect (Biswas & Rudra).
Butyrophenones
Butryophenones are a group of medications that work on the D2 dopamine
receptors (Chatterjee et al., 2011). The two drugs in this class that have antiemetic
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properties and are used to prevent PONV are droperidol and haloperidol. Prior to 2001,
droperidol was a very popular medication used alone and in combination for prevention
of PONV. It was used at low doses, 0.625 – 1.25 mg and it was effective. However, this
drug class has many side effects and in 2001, the FDA released a black box warning for
droperidol. This was due to a risk of QT prolongation which led to arrhythmias when this
drug was used. The black box warning referred to using much higher doses of doperidol
than would be used for PONV, however it is mandatory to now have cardiac monitoring
on the patient when using this medication (Chatterjee et al).
Haloperidol also has antiemetic properties, and has been studied more since the
black box warning on droperidol. Haloperidol was originally used to treat psychiatric
disorders, and still is to this day. However, to prevent PONV, the dose used is 0.5-2 mg
(Gan et al., 2014). At this lower dose other side effects such as sedation and cardiac
arrhythmias were not seen with haloperidol though it does still carry a risk of QTc
prolongation. Aouad et al. (2007) compared the effects of haloperidol and Zofran. This
study included 93 females undergoing a gynecologic procedure under general anesthesia.
When 1 mg of haloperidol was compared with 4 mg of Zofran, there was no difference in
the QTc effect. There was also no significant difference in the PONV incidence; 40.7%
(n = 11) of the haloperidol group experienced PONV and the Zofran group had an
incidence of 48.2% (n = 13) (Aouad et al.).
Another known side effect of haloperidol is extrapyramidal symptoms. However,
a meta-analysis of haloperidol as an antiemetic showed that only one in 806 patients who
were given 4 mg of haloperidol exhibited any extrapyramidal symptoms (Buttner,
Walder, Elm & Tramer, 2004). Out of all the studies that the meta-analysis discussed a
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total of 1,397 patients received haloperidol at different doses and no patients receiving a
dose of haloperidol less than 4 mg exhibited extrapyramidal symptoms (Buttner et al).
Since haloperidol is a dopamine antagonist it should be used with extreme caution with
any patients who have Parkinson’s disease, restless leg syndrome, or any other disease
that is related to a dopamine insufficiency (Flood et al., 2015).
The Buttner et al. (2004) meta-analysis examined a total of 21 studies using
haloperidol to treat nausea and vomiting. However, this literature review will focus on
the evidence combined from four studies in the meta-analysis that examined the effect of
haloperidol on preventing PONV. Intravenous dosages were tested at 5 mg and 4 mg.
Both significantly decreased nausea and vomiting, although the antinausea effect was
greater. With haloperidol, the average report of nausea was 16.4% (n = 90/548), whereas
with the placebo it was 43.8% (n = 237/541). The results of this meta-analysis provide
evidence that haloperidol is effective as an antiemetic. This systematic review will focus
on more recent studies to evaluate the most up to date evidence on the topic.
Next, the theoretical framework guiding this systematic review will be discussed.

14
Theoretical Framework
The PRISMA framework was used to guide this project. PRISMA is an evidencebased set of items that helps authors improve the reporting in a systematic review as well
as assess the strengths and weaknesses of a systematic review (Moher, Liberati, Tetzlaff
& Altman, 2009). The PRISMA statement consists of a flow diagram and a checklist.
The flow diagram is illustrated in Appendix A and guides the user through identifying,
screening, and checking eligibility of the articles that will ultimately be included in the
systematic review (Moher et al).
The checklist assists the author in structuring and writing the systematic review.
The checklist, shown in Appendix B, consists of 27 items and includes major sections of
a systematic review and what is to be included in each section (Moher et al., 2009). This
is helpful to make sure that every part necessary to a systematic review is included.
Inclusion and exclusion criteria will be applied to select articles that will be analyzed.
Utilizing PRISMA as a framework will help to create a thorough and pertinent systematic
review (Moher et al.).
In addition to PRISMA, the Critical Appraisal Skills Programme (CASP) was
used to evaluate each article that was selected to be included in the systematic review.
The purpose of CASP is to help determine the scientific integrity of the research being
evaluated. There is a CASP checklist, illustrated in the methods section, exclusively for
systematic reviews that will help with appraising the relevant information. There are
three main sections to the CASP checklist. The first section is focused on the validity of
results. There are six questions used to help the author identify if the results are valid.
The second section is focused on what the results are. This helps to determine what each
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study is showing. The third section is focused on how these results can be applied to
practice (Critical Appraisal Skills Programme, 2017).
Next, the methods will be discussed.
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Method
Purpose
This systematic review examined the efficacy of haloperidol in prophylactically
treating postoperative nausea and vomiting in patients who have undergone a
laparoscopic surgery under general anesthesia.
Inclusion/Exclusion Criteria
The inclusion criteria for this systematic review were randomized control trials,
subjects over 18 years old and must have had a laparoscopic surgical procedure with
general anesthetic; haloperidol must have been used prophylactically for PONV, with the
article written in English, and under 10 years old. The study must have included data on
the incidence of PONV for 24 hours postoperatively.
The exclusion criteria included articles not written in English, over 10 years old,
participants less than 18 years old, not randomized control trials, studies that did include
laparoscopic surgical procedures and studies that do not measure incidence of PONV for
24 hours postoperatively.
Search Strategy
To gather the research that is available, a detailed search included the databases
PubMed, CINAHL, and Medline. The search words used were Haldol or haloperidol,
postoperative nausea and vomiting, and laparoscopic surgery. The target studies were
articles in English that were randomized control trials. The PRISMA flowchart was used
to select articles that would be evaluated in the systematic review. On the following page
there is the completed PRISMA four stage flow diagram, Figure 1. This demonstrates the
selection process of articles included in the systematic review.
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Identification

PRISMA 2009 Flow Diagram

Records identified through
database searching
(n =7 )

Additional records identified
through other sources
(n = 2)

Eligibility

Screening

Records after duplicates removed
(n = 7 )

Records screened
(n = 7 )

Records excluded
(n = 2 )

Full-text articles assessed
for eligibility
(n = 5 )

Full-text articles excluded,
with reasons
(n = 0 )

Included

Studies included in
qualitative synthesis
(n = 5)

Studies included in
quantitative synthesis
(meta-analysis)
(n = 5)

Figure 1. Completed PRISMA Flow Diagram (Moher et al., 2009).
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Data Collection
Once the articles that were included in the systematic review were selected, each
article was reviewed and presented in detailed data collection tables. One table examined
the design of the study (Table 1). The other data collection table illustrated the outcomes
of each study (Table 2).

Table 1
Study Demographics
Citation
Purpose

Design

Sample

Surgical
Procedure

Method

Table 2
Outcomes of the Study
Citation
Nausea and
Vomiting

Pain Scores

Adverse Side
Effects

Limitations

The CASP checklist for systematic reviews, illustrated in Table 3 on the next
page, was used to critically appraise each article and determined the scientific integrity
(Critical Appraisal Skills Programme, 2017). This checklist helped to show how relevant
the outcomes were from each study as well as how scientifically strong the evidence was.
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Table 3
CASP Checklist
A. Are the results of the trial valid?

YES

CAN’T
TELL

NO

YES

CAN’T
TELL

NO

1. Did the trial address a clearly focused issue?
2. Was the assignment of patients to treatments
randomized?
3. Were all of the patients who entered the trial
properly accounted for at its conclusion?
4. Were patients, health workers, and study
personnel “blind” to treatment?
5. Were the groups similar at the start of the
trial?
6. Aside from the experimental intervention,
were the groups treated equally?
B. What are the results?
7. How large was the treatment effect?
8. How precise was the estimate of the
treatment effect?
C. Will the results help locally?
9. Can the results be applied in your context?
10. Were all clinically important outcomes
considered?
11. Are the benefits worth the harms and costs?

Descriptive Data Analysis
The data were synthesized into the data collection tables. A final table was created
for a cross-study analysis (Table 4). This table combined the information from the
different studies and compared the pertinent outcomes from all the studies together. The
results from each individual study and the cross-study analysis was then discussed in the
results section of the systematic review.
The table used for the cross-study analysis is illustrated in Table 4.
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Table 4
Cross-Study Analysis
Study
Nausea & Vomiting
number
1

Pain Scores

2
3
4
5

Next, the results will be presented.

Side Effects
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Results
Five studies met the criteria for this systematic review. All of these studies
evaluated how the use of prophylactic haloperidol effected PONV in patients who had
undergone laparoscopic surgical procedures. The tables that illustrate the design details of
each study can be found in Appendix C, Tables 1-5. Tables that illustrate the results of
each study are shown in Appendix D, Tables 1-5. The critical appraisal tables for each
study can be found in Appendix E. Appendix F illustrates the cross study analysis.
The study conducted by Benevides, Oliveira and Aguilar-Nscimento (2012) was
to evaluate the intensity of nausea, pain and the number of vomiting episodes on
postoperative patients who had undergone a laparoscopic sleeve gastrectomy (Appendix
C-1). There were 90 patients involved in this double-blind randomized control trial.
These patients were divided into three groups. Each group was medicated with a different
combination of prophylactic antiemetic medications. Group O received ondansetron only.
Group DO received dexamethasone and ondansetron. Group HDO received haloperidol,
dexamethasone and ondansetron. Throughout the procedure the anesthetic and surgical
techniques were standardized. The postoperative diet was also standardized, advancing
based on patients’ acceptance. The authors utilized a verbal numeric scale of nausea
(VNSN) and a verbal numeric scale of pain (VNSP) to evaluate the patients’ pain and
nausea. They monitored the number of vomiting or retching episodes.
The results of this study can be seen in Appendix D-1. There was a significant
decrease in nausea between Group O and Group HDO (p = 0.001), with Group O having
a mean intensity score of 4 and group HDO had a score of 1.5. With the episodes of
vomiting, the results showed a trend towards statistical significance, with episodes of
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vomiting lower in group HDO than group O (p = 0.052). Group HDO experienced 0.63 ±
1.2 episodes of vomiting compared to group O 1.10 ± 1.2, and group DO 0.83 ± 2. The
pain scores were lower in group HDO than Group O (p = 0.0.46), where the mean
intensity score for group O was 2.2 and for Group HDO it was 1. Some limitations to
this study were that there was no control group for this experiment and the sample size
was relatively small.
The critical appraisal of this article can be seen in Appendix E-1. This table
illustrates that the article did address the focused areas. The assignment of patients was
randomized, all patients were accounted for at the end of the study and all personnel who
participated in this study were blind to the treatment. All groups were treated equally
with the exception of the experimental intervention. The number of patients in the study
was relatively small at 90, but the results did show decreased nausea, vomiting and pain
scores. Not all clinical outcomes were considered statistically important.
The study by Chu et al., (2008) evaluated the prophylactic effect of haloperidol
given alone or in combination with dexamethasone on PONV in patients who underwent
a laparoscopic assisted vaginal hysterectomy (Appendix C-2). This was a clinical doubleblind randomized control trial. Four hundred patients were selected for this trial; 28 of the
patients were excluded from analysis. The patients were divided into five groups. The
first group was Group S, the control group, in which patients were medicated with saline;
Group D patients received droperidol; Group H patients received haloperidol; and Group
Dx patients received dexamethasone and Group H + Dx patients received haloperidol and
dexamethasone. All patients were medicated with the study drug 15 minutes after the
induction of anesthesia. Anesthesia and surgical technique were standardized. The
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authors noted that they used standard monitoring as well as measured the patients’ QT
intervals. The authors documented PONV by including the incidence of nausea,
vomiting, and rescue antiemetics used. Postoperative pain was assessed using a visual
analog scale (VAS). Also, any extrapyramidal side effects were noted.
The results are summarized in Appendix D-2. Group S had 49 patients (65%) who
experienced PONV; Group D had 28 patients (36%); Group H had 27 patients (37%);
Group Dx had 28 patients (38%); and Group H + Dx had the lowest incidence where 14
patients (19%) experienced PONV (p = 0.05). There was no statistical difference between
Group H, Group Dx and Group D. All of the groups experienced less PONV than Group
S. There was no statistical difference in postoperative pain scores between groups.
Extrapyramidal side effects were seen in Group D, where two patients experienced motor
restlessness and Group H where one patient experienced it. There was no statistical
difference between any of the groups. A limitation of this study was that the authors did
not utilize a VAS to score patients’ nausea intensity, making the results less sensitive.
The critical appraisal for this study can be found in Appendix E-2. This study was
a randomized double-blind trial. All groups were similar in the beginning of this trial and
all participants were accounted for at the end. It had a large sample size of 400 people
and demonstrated that haloperidol decreased nausea and vomiting. This study did address
the focus areas.
Feng et al. (2009) evaluated the prophylactic effect of haloperidol plus
ondansetron on PONV with patients undergoing laparoscopic cholecystectomies. The
design of this study is summarized in Appendix C-3. This was a clinical double-blind
randomized control trial. There were 210 patients to begin this trial, with 18 of them
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excluded. The patients were divided up into three groups. Group H patients were
medicated with saline and haloperidol. Group O patient were medicated with ondansetron
and saline. Group H + O patients were medicated with haloperidol and ondansetron. The
anesthesia, mechanical ventilation, and surgical technique were all standardized
throughout. Standard monitoring as well as QTc intervals were recorded. All of the
patients were monitored for 24 hours postoperatively. The authors recorded the incidence
and severity of PONV, the severity of postoperative pain, and the occurrence of adverse
side effects.
The results of this study can be seen in Appendix D-3. These authors found that
Group H + O experienced less PONV than the other groups (p < 0.05). Group H had 25
patients (39%) experience PONV, Group O had 25 patients (38%), and Group H + O had
13 patients (21%). The postoperative pain scores were similar in all three groups. Two
patients out of the study, one in group H and one in group H + O, experienced an adverse
side effect of restlessness. A limitation in this study was that there was no true control
group.
The critical appraisal for this study is summarized in Appendix E-3. This showed
that the study was a double-blinded study that addressed the focus areas. The sample size
was 210 people undergoing the same kind of surgery and results demonstrated that
haloperidol plus ondansetron decreased nausea and vomiting. The findings can be applied
to similar population groups and the benefits were shown to be worth the harms and
costs.
Joo et al. (2015) conducted a study (Appendix C-4) that evaluated at which dose
haloperidol could be combined with dexamethasone to prevent PONV without adverse
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side effects in patients undergoing gynecological laparoscopic procedures. It was a
clinical double-blind randomized trial. There were 150 patients involved in the study.
They were divided into three groups with all of the groups were medicated with
dexamethasone. Group H0 received saline with the dexamethasone; Group H1 received 1
mg of haloperidol with the dexamethasone; and Group H2 received 2 mg of haloperidol
with dexamethasone. Anesthesia, ventilation and surgical technique were all
standardized. The authors monitored the incidence of PONV, pain intensity, rescue
antiemetics used, and adverse side effects.
Groups H1 and H2 had a significantly lower incidence of PONV than Group H0.
In Group H0 21 patients (42%) experienced PONV; Group H1 11 patients (22%)
experienced it; and Group H2 had 10 patients (20%) who experienced PONV (p<0.017).
There were no significant differences in pain scores across all three groups. Group H2 did
have a significant increase in sedation compared to the other two groups where Group H0
and Group H1 had an average VAS sedation score of 3.5 and Group H2 had an average
score of 5 (p < 0.001). There were no cardiac or EPS seen in any of the groups. These
results are summarized in Appendix D-4. Some limitations of this study were that there
was no real control group since all patients were medicated with dexamethasone. Also,
the sample size was relatively small.
The critical appraisal for this study can be seen in Appendix E-4. This was a
double-blind randomized study. All groups were similar at the start of the trial and were
treated equally with the exception of the experimental intervention. All patients were
accounted for at the end of the study. The sample size was smaller, with 150 patients. It
did have a precise estimate of the treatment effect showing that haloperidol and
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dexamethasone decreased nausea and vomiting. These results can be applied to similar
populations.
The study by Wang et al. (2008) evaluated the prophylactic effect of low-dose
haloperidol on post-operative nausea and vomiting in women undergoing ambulatory
laparoscopic surgery. The design of this study is summarized in Appendix C-5. It was a
randomized double-blind and placebo-controlled study. There was a total of 150 patients
in the study, and they were divided into three groups. There was a saline group, which
was medicated with saline; a haloperidol group that was medicated with 1 mg of
haloperidol; and a droperidol group which was medicated with 0.625 mg of droperidol.
The anesthesia and surgical procedures were standardized. The medications were all
given 15 minutes after induction of anesthesia. The authors recorded the intensity of the
postoperative pain using a VAS scale 0-10. The incidence of PONV was collected by
telephone 24 hours postoperatively. All patients were monitored for any adverse side
effects.
The results of this study can be seen in Appendix D-5. The haloperidol and
droperidol group both experienced significantly less PONV than the saline group. In the
haloperidol group 14 patients (31%) experienced PONV; the droperidol group had 14
patients (32%) and the saline group had 29 patients (62%) who experienced PONV
(p<0.05). There were no differences found in postoperative pain scores between the
groups. There was no difference in sedation scores and no EPS were noted. A limitation
of this study was that since it was done with ambulatory surgery the authors had to rely
on getting information over the telephone after the patient was discharged and it was not
done under direct observation.
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The critical appraisal table for this study is found in Appendix E-5. This study
was a randomized double-blind study. All participants were treated similarly aside from
the experimental intervention. It was a relatively small sample size with 150 participants.
This study did show a precise treatment effect with decreased nausea and vomiting. The
benefits were shown to be worth the harms and costs.
The cross-study analysis can be seen in Appendix F. All five studies showed a
statistically significant decrease in PONV when haloperidol was used to prophylactically
treat it. Pain scores were not significantly different except for in the study conducted by
Benevides et al. (2012), which showed a decrease in pain in the group that was medicated
with haloperidol. Benevides et al. did not identify any adverse side effects of haloperidol
in their study. The study by Chu et al. (2008) noted two patients who experienced the
EPS symptom of motor restlessness; Feng et al. (2009) also noted two patients in their
study experienced motor restlessness. In the study by Joo et al. (2015), there were no
extrapyramidal side symptoms (EPS) noted; however, in groups medicated with 2 mg of
haloperidol there was increased sedation levels. Wang et al. (2008) stated there were no
adverse side effects of haloperidol noted. Overall, the studies all concluded that
haloperidol can be used safely as a medication to prophylactically treat PONV.
The next section will discuss the summary and conclusions.
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Summary and Conclusions
Postoperative nausea and vomiting is a continuous problem that affects up to 30%
of all patients undergoing general anesthesia (Pierre & Whelan, 2013). This complication
can increase recovery time and length of stay for the patients. This is very uncomfortable
for the patients and has led to decreased satisfaction scores (Flood et al., 2015). It can
also be dangerous for the patient putting them at risk for wound dehiscence and aspiration
(Nagelhout & Plaus, 2014). There are many identified risk factors for PONV. The patient
specific risk factors are female gender, age less than 50, nonsmokers and a history of
PONV or motion sickness (Nagelhout & Plaus). Patients who are at determined to be at
high risk for PONV have an 80% chance of experiencing it (Pierre & Whelan, 2013).
This is why it is so important to prevent a patient from experiencing this complication.
Currently, a prophylactic approach to preventing PONV is being used. The
vomiting center of the brain can be found in the NTS and there are several different
neurotransmitters that control the activity in the vomiting center. There is also the
chemoreceptor trigger zone which detects noxious chemicals (Flood et al., 2015).
Because PONV can be triggered so many different ways, there are a number of ways that
we can prevent it. It has been shown that many medications can prevent PONV by
working on different receptor sites, but that when they are used in combination with each
other they can have an additive effect (Pierre & Whelan, 2013). One medication that is
being used to prophylactically treat PONV is haloperidol. This medication is an
antagonist of the D2 dopamine receptor, preventing PONV at the vomiting center (Flood
et al.).
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This systematic review evaluated randomized control trials that examined how
haloperidol worked as a prophylactic agent of PONV. The PRISMA framework was used
as a theoretical framework to guide the selection of the articles used in the systematic
review. CASP was used to critically appraise each study. PubMed, CINAHL, and
Medline were searched for haloperidol, postoperative nausea and vomiting, and
laparoscopic surgery. Once the inclusion and exclusion criteria were applied, there were
five articles that were included in this systematic review. Each study was evaluated and
data were collected in two tables and the CASP table.
The main findings of this systematic review showed that haloperidol was
successful in reducing PONV. Every study showed that this medication can significantly
reduce the number of vomiting episodes and accounts of nausea reported. Some of the
articles discussed the side effects of haloperidol, and the occurrence of these was not
found to be statistically significant. Over all, the studies showed that using haloperidol in
a multimodal approach to prevent PONV was even more successful than using one
medication alone.
These findings can be directly applied to similar populations of patients
undergoing general anesthesia and directly answers the focus problem. There are some
limitations to this systematic review. There was a limited number of studies included in
this systematic review. Also, most of the studies that were included had a limited sample.
In conclusion, this systematic review supports the use of haloperidol as a
medication to be used in preventing PONV. The studies found haloperidol works better
when being used in a multimodal approach with other prophylactic medications for
PONV. The next section of this paper will discuss the implications in nursing practice.
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Recommendations and Implications for Advanced Nursing Practice
This systematic review yielded information that can be utilized specifically in
advanced nursing practice. Postoperative nausea and vomiting is a problem that every
anesthesia provider must consider when administering general anesthesia. Part of the
nurse anesthetist role as an advanced provider is to make critical thinking decisions and
provide the best possible care to each patient. Prophylactically treating a patient with a
multimodal approach the incidence of PONV can be greatly decreased. The multimodal
approach should be implanted in anesthesia provider practice to provide better patient
outcomes.
For an anesthesia provider to utilize haloperidol as one medication in a
prophylactic approach, they need to understand the mechanism of action, efficacy and
possible side effects. Providers should also understand the pathophysiology of PONV and
the risk factors so that they can identify patients that are more likely to suffer from
PONV. Educating anesthesia providers on PONV, a prophylactic multimodal approach to
prevent PONV, and specific medications such as haloperidol is needed.
CRNA’s can be instrumental in developing and implementing evidence-based
guidelines to prevent PONV. Utilizing a risk scoring system, such as the Apfel risk score,
to identify patients at high risk of PONV should be a standardized practice since patients
at high risk of PONV have an incidence of up to 80%. Guidelines should discuss a
prophylactic approach with two or more medications for these patients and haloperidol
should be one of the standardized options. Every medication choice must be patient
specific but having guidelines and options can help educated practitioners make the best
decisions.

31
Further research is needed on this topic. There are many medications that can be
utilized for prevention of PONV, with new ones being developed. Studies to determine
how effective and safe each of these medications are should be routinely performed.
Also, this systematic review specifically evaluated studies that involved laparoscopic
surgical procedures yet PONV is a possible complication of all general surgeries. The
efficacy of haloperidol and other antiemetic medications should be studied on all kinds of
general surgery.
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Appendix A

Identification

PRISMA 2009 Flow Diagram

Records identified through
database searching
(n = )

Additional records identified
through other sources
(n = )

Eligibility

Screening

Records after duplicates removed
(n = )

Records screened
(n = )

Records excluded
(n = )

Full-text articles
assessed for eligibility
(n = )

Full-text articles
excluded, with reasons
(n = )

Included

Studies included in
qualitative synthesis
(n = )

Studies included in
quantitative synthesis
(meta-analysis)
(n = )

(PRISMA Transparent Reporting of Systematic Reviews and Meta-Analyses, 2015)
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Appendix B
Section/topic

#

Checklist item

1

Identify the report as a systematic review, meta-analysis, or both.

2

Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility
criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions
and implications of key findings; systematic review registration number.

Rationale

3

Describe the rationale for the review in the context of what is already known.

Objectives

4

Provide an explicit statement of questions being addressed with reference to participants, interventions,
comparisons, outcomes, and study design (PICOS).

Protocol and
registration

5

Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide
registration information including registration number.

Eligibility criteria

6

Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered,
language, publication status) used as criteria for eligibility, giving rationale.

Information
sources

7

Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify
additional studies) in the search and date last searched.

Search

8

Present full electronic search strategy for at least one database, including any limits used, such that it could be
repeated.

Study selection

9

State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable,
included in the meta-analysis).

Data collection
process

10

Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any
processes for obtaining and confirming data from investigators.

Data items

11

List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and
simplifications made.

Risk of bias in
individual studies

12

Describe methods used for assessing risk of bias of individual studies (including specification of whether this was
done at the study or outcome level), and how this information is to be used in any data synthesis.

Summary
measures

13

State the principal summary measures (e.g., risk ratio, difference in means).

Synthesis of
results

14

Describe the methods of handling data and combining results of studies, if done, including measures of
consistency (e.g., I2) for each meta-analysis.

Risk of bias
across studies

15

Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective
reporting within studies).

Additional
analyses

16

Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done,
indicating which were pre-specified.

Study selection

17

Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions
at each stage, ideally with a flow diagram.

Study
characteristics

18

For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period)
and provide the citations.

Risk of bias
within studies

19

Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).

Results of
individual studies

20

For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.

Synthesis of
results

21

Present results of each meta-analysis done, including confidence intervals and measures of consistency.

Risk of bias
across studies

22

Present results of any assessment of risk of bias across studies (see Item 15).

Additional
analysis

23

Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item
16]).

Summary of
evidence

24

Summarize the main findings including the strength of evidence for each main outcome; consider their relevance
to key groups (e.g., healthcare providers, users, and policy makers).

Limitations

25

Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of
identified research, reporting bias).

Conclusions

26

Provide a general interpretation of the results in the context of other evidence, and implications for future
research.

27

Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for
the systematic review.

TITLE
Title
ABSTRACT
Structured
summary
INTRODUCTION

METHODS

RESULTS

DISCUSSION

FUNDING
Funding

Reported
on page #
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Appendix C
C-1: Benevides, M. L., Oliveira, S., & Aguilar-Nascimento, J. E., (2012). Combination of haloperidol,
dexamethasone, and ondansetron reduces nausea and pain intensity and morphine consumption after laparoscopic
sleeve gastrectomy. Revista Brasileira De Anestesiologia, 63(5), 404-409.
Purpose
Design
Sample
Surgical Procedure Method
To evaluate the
intensity of nausea
and pain and the
number of
vomiting episodes
in postoperative
patients.

A clinical doubleblind randomized
control trial with
three groups, each
with 30 patients.
Group O received
ondansetron only;
Group DO
received
dexamethasone
and ondansetron;
Group HDO
received
haloperidol,
dexamethasone,
and ondansetron

90 Patients were
included in total.
They were all
greater than 18
years old, a mix of
males and females
and BMI >35.
ASA levels I – III
were included.

Laparoscopic
sleeve
gastrectomy.

Anesthetic technique was
standardized with induction
and maintenance medications
based on ideal body weight.
Surgical technique was
standardized.
Postoperative diet was
standardized based on patient’s
acceptance.
The Verbal numeric scale of
nausea (VNSN) and the verbal
numeric scale of pain (VNSP)
were utilized to evaluate
nausea and pain.
Nausea and pain were
evaluated 2, 12, 24, and 36
hours postoperatively.
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C-2: Chu, C., Shieh, J., Tzeng, J., Chen, J., Lee, Y., Ho, S., & Wang, J. (2008). The prophylactic effect of haloperidol plus
dexamethasone on postoperative nausea and vomiting in patients undergoing laparoscoically assisted vaginal
hysterectomy. Ambulatory Anesthesiology, 106(5), 1402-1406.
Purpose
Design
Sample
Surgical Procedure Method
A clinical double- A total of 400
LaparoscopicPatients were medicated 15 minutes
To evaluate the
patients, all
assisted vaginal
after the induction of anesthesia.
prophylactic effect blind randomized
control trial with a women. All
hysterectomy.
Anesthesia was standardized for all
of haloperidol
control group.
patients were ASA
patients. Ventilation was controlled
given alone or in
There were five
level I or II.
mechanically and adjusted to
combination with
maintain end-tidal carbon dioxide.
dexamethasone on groups, each with Exclusion criteria
80
patients.
Group
included
difficult
Standard monitoring was used and
PONV.
S received a
airway, obesity,
QT intervals were measured.
placebo. Group D pregnancy,
Patients were observed
received
psychiatric illness,
postoperatively for 24 hours. The
droperidol. Group major organ
incidence and severity of PONV
H received
disease. 28 of the
were documented including the
haloperidol. Group 400 patients
incidence of nausea, vomiting,
Dx received
enrolled were
nausea and vomiting, and rescue
dexamethasone.
excluded from the
antiemetics used. Postoperative pain
And Group H +
analysis.
was assessed 24 hours
Dx received
postoperatively using the visual
haloperidol and
analog scale (VAS). All
dexamethasone.
extrapyramidal side effects noted in a
24 hour period were documented.

41

C-3: Feng, P., Chu, K., Lu, I., Shieh, J., Tzeng, J., Ho, S., … Chu, C. (2009). Haloperidol plus ondansetron prevents
postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy. Acta Anaesthesiol Taiwan,
47(1), 3-9.
Purpose
Design
Sample
Surgical Procedure Method
A clinical double- A total of 210
Laparoscopic
Anesthesia was standardized in
To evaluate the
patients. Each
Cholecystectomy. all patients. Ventilation was
prophylactic effect blind randomized
mechanically controlled and
of haloperidol plus control trial. There group had 70
were three groups. patients. All
adjusted to maintain end-tidal
ondansetron on
Group H was
patients were ASA
carbon dioxide. QTc intervals
PONV.
medicated with
class I or II.
were measured during the
saline and
Exclusion criteria
procedure.
haloperidol; Group included evidence
All patients were observed for
O was medicated
of a difficult
24 hours postoperative. The
with ondansetron
airway, obesity,
incidence and severity of
and saline; Group pregnancy,
PONV, the severity of
H + O was
psychiatric illness,
postoperative pain, and the
medicated with
major organ
occurrence of postoperative
haloperidol and
disease, QTc
adverse effects such as sedation
ondansetron.
interval >440, or
and EPS were all recorded.
consumption of
Nausea was measure with a
antiemetics within
verbal rating scale from 0-10.
24 hours of the
Episodes of vomiting was either
study. 18 of the
retching or expulsion of stomach
210 patients were
contents. Postoperative pain was
excluded.
scaled using a visual analog
scale from 0-10.
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C-4: Joo, J., Park, Y., Baek, J., & Moon, Y. (2015). Haloperidol dose combined with dexamethasone for ponv
prophylaxis in high-risk patients undergoing a gynecological laparoscopic surgery: a prospective, randomized, doubleblind, dose-response and placebo-controlled study. BMC Anesthesiology, 15(99), 1-6.
Purpose
Design
Sample
Surgical Procedure Method
Gynecological
Anesthesia was standardized,
To identify which A clinical double- There was a total
blind randomized
of 150 female
laparoscopic
titrated to maintain a BIS value of
dose of
control trial with a adult patients
surgeries.
40-60. All patients received 5 mg
haloperidol could
involved in this
dexamethasone IV during
be combined with control group.
Patients were
study. They were
induction. Ventilation was
dexamethasone
divided
up
into
all
ASA
class
I
or
controlled mechanically and
without adverse
three groups. All
II, ages between
adjusted to maintain end-tidal
effects to prevent
of
the
groups
were
20-65.
All
patients
carbon dioxide 30-40. Haloperidol
PONV in high-risk
medicated with
were non-smokers
was administered approximately
patients.
dexamethasone.
and used opioids
30 min before the end of
Group H0 was
for postoperative
anesthesia. All patients were given
medicated with
pain control. One
a PCA for postoperative pain
saline; Group H1
patient was
control.
The authors monitored the
medicated with 1
excluded due to
mg of haloperidol; intraoperative
incidence of postoperative nausea
and vomiting, pain intensity,
Group H2 was
conversion to an
medicated with 2
open laparotomy.
rescue antiemetics used, and
mg haloperidol.
adverse side effects. Nausea was
graded as tolerable or intolerable.
Postoperative pain was measured
using a visual analogue scale from
0-10. Sedation was assessed on a
VAS scale 0-10.
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C-5: Wang, T., Liu, Y., Chu, C., Shieh, J., Tzeng, J., & Wang, J. (2008). Low-dose haloperidol prevents post-operative
nausea and vomiting after ambulatory laparoscopic surgery. Acta Anaesthesiologica Scandinavica, 52, 280-284.
Purpose
Design
Sample
Surgical Procedure Method
A randomized,
A total of 150
Ambulatory
The anesthesia regimen and the
To evaluate the
patients, all
laparoscopic
surgical procedure were
prophylactic effect double-blind and
placebo-controlled women, were
surgery.
standardized. Ventilation was
of low-dose
study. There were involved in this
controlled mechanically and adjusted
haloperidol on
three groups, each study. Each group
to maintain an end-tidal carbon
post-operative
with 50 patients.
had 50 patients.
dioxide level of 30-40. The Haldol,
nausea and
The
Haldol
group
All
patients
were
droperidol, or saline was
vomiting in
was medicated
ASA class I or II.
administered 15 minutes after
women.
with 1 mg of
14 patients were
induction of anesthesia.
Haldol. The
excluded during
The intensity of postoperative pain
droperidol group
the study due to
was measured using a visual
was medicated
surgical reasons or
analogue scale of 0-10. The presence
with 0.625 mg of
incomplete data
of PONV was collected by telephone
droperidol. The
after the patients
24 hours after surgery. The
saline group
left the hospital.
researchers monitored for adverse
received saline.
side effects.
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Appendix D

D-1: Benevides, M. L., Oliveira, S., & Aguilar-Nascimento, J. E., (2012). Combination of haloperidol, dexamethasone, and
ondansetron reduces nausea and pain intensity and morphine consumption after laparoscopic sleeve gastrectomy. Revista
Brasileira De Anestesiologia, 63(5), 404-409.
Nausea and Vomiting

Pain Scores

Adverse Side Effects

Limitations

The mean intensity of nausea
through the VNSN for Group
O was 4; Group DO it was
2.1; Group HDO it was 1.5
(p = 0.001).
Group HDO experienced
0.63 ± 1.2 episodes of
vomiting compared to group
O 1.10 ± 1.2, and group DO
0.83 ± 2 (p = 0.052).

The mean intensity of pain
through the VNSP for group
O was 2.2; Group DO it was
1.9; Group HDO it was 1 (p
= 0.046).

This study did not monitor
for adverse side effects.

There was not a control
group for this experiment.
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D-2: Chu, C., Shieh, J., Tzeng, J., Chen, J., Lee, Y., Ho, S., & Wang, J. (2008). The prophylactic effect of haloperidol plus
dexamethasone on postoperative nausea and vomiting in patients undergoing laparoscopically assisted vaginal hysterectomy.
Ambulatory Anesthesiology, 106(5), 1402-1406.
Postoperative Nausea and
Pain Scores
Adverse Side Effects
Limitations
Vomiting
In Group S, 49 patients
(65%) experienced PONV.
In Group D, 28 patients
(36%); Group H 27 patients
(37%); Group Dx 28 patients
(38%); Group H + Dx 14
patients (19%) experienced
PONV (p = 0.05).

All groups reported VAS
scores of 2-4 on a scale of 010. There was no significant
differences determined
between groups.

Group D had two patients
that experienced EPS, motor
restlessness. Group H had
one patient that experienced
motor restlessness. No
statistical significant
differences were determined
between groups.

The results are not sensitive
enough to detect the antinausea effect of the
antiemetics tested because
the authors did not use a
VAS score to evaluate the
nausea severity.
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D-3: Feng, P., Chu, K., Lu, I., Shieh, J., Tzeng, J., Ho, S., … Chu, C. (2009). Haloperidol plus ondansetron prevents
postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy. Acta Anaesthesiol Taiwan, 47(1),
3-9.
Postoperative Nausea and
Pain Scores
Adverse Side Effects
Limitations
Vomiting
Using the VAS, with a score Two patients reported an
No control group was used in
Group H had 25 patients
range from 0-10, Group H
EPS of restlessness. One was this study.
(39%) experience PONV;
scored 2.2 ± 1.4; Group O
in Group H, and one was in
scored 2.1 ± 1.3; Group H + Group H + O.
Group O had 25 patients
(38%); and Group H + O had O scored 1.9± 0.8.
13 patients (21%) (p<0.05).
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D-4: Joo, J., Park, Y., Baek, J., & Moon, Y. (2015). Haloperidol dose combined with dexamethasone for ponv prophylaxis
in high-risk patients undergoing a gynecological laparoscopic surgery: a prospective, randomized, double-blind, doseresponse and placebo-controlled study. BMC Anesthesiology, 15(99), 1-6.
Postoperative Nausea and
Pain Scores
Adverse Side Effects
Limitations
Vomiting
In Group H0 21 patients
Group H0 reported an
There was no significant
There was no control group,
(42%) experienced PONV;
average VAS score of 2.2;
difference in sedation scores as all patients received
Group H1 reported 2.8;
between Group H0 and H1,
dexamethasone.
Group H1 had 11 patients
average on the VAS score
Relatively small sample size,
(22%); and Group H2 had 10 Group H2 reported 2.2.
patients (20%) who
was a 3.5. There was an
leading to these results being
experienced PONV
increased sedation scores in
exploratory rather than
(p<0.017).
Group H2, where the average confirmatory results.
VAS score was a 5
(p<0.001). No cardiac
arrhythmias or EPS were
observed.
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D-5: Wang, T., Liu, Y., Chu, C., Shieh, J., Tzeng, J., & Wang, J. (2008). Low-dose haloperidol prevents post-operative
nausea and vomiting after ambulatory laparoscopic surgery. Acta Anaesthesiologica Scandinavica, 52, 280-284.
Postoperative Nausea and
Vomiting
In the haloperidol group 14
patients (31%) experienced
PONV; the droperidol group
had 14 patients (32%) and
the saline group had 29
patients (62%) who
experienced PONV (p<0.05).

Postoperative Pain Score

Adverse Side Effects

Pain reports were 1-3 in all
three groups with no
differences found between
them.

The level of sedation was
scored 1-2 in all three
groups, with no differences
found. There were no
observed EPS in any group.

Limitations
Due to the fact that this study
was done with ambulatory
surgery, the authors had to
rely on getting information
on the phone after the patient
was discharged and not
actual observed results.
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Appendix E
Critical Appraisal Skills Programme (CASP) Randomized Control Trials Checklist
E-1: Benevides, M. L., Oliveira, S., & Aguilar-Nascimento, J. E., (2012). Combination
of haloperidol, dexamethasone, and ondansetron reduces nausea and pain intensity and
morphine consumption after laparoscopic sleeve gastrectomy. Revista Brasileira De
Anestesiologia, 63(5), 404-409.
A) Are the results of the trial valid?
YES
CAN’T
NO
TELL
1. Did the trial address a clearly focused
issue?
2. Was the assignment of patients to
treatments randomized?
3. Were all of the patients who entered the
trial properly accounted for at its
conclusion?
4. Were patients, health workers and study
personnel “blind” to treatment?
5. Were the groups similar at the start of
the trial?
6. Aside from the experimental
intervention, were the groups treated
equally?

X
X
X

X
X
X

B) What are the results?
7. How large was the treatment effect?

Not discussed.

8. How precise was the estimate of the
treatment effect?

Not discussed.

C) Will the results help locally?

YES

CAN’T
TELL

NO

9. Can the results be applied in your
X
context?
(or to the local population?)
10. Were all clinically important outcomes
X
considered?
11. Are the benefits worth the harms and
X
costs?
Note. This study did not mention if there were any adverse side effects of haloperidol
noted.
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Critical Appraisal Skills Programme (CASP) Randomized Control Trials Checklist
E-2: Chu, C., Shieh, J., Tzeng, J., Chen, J., Lee, Y., Ho, S., & Wang, J. (2008). The
prophylactic effect of haloperidol plus dexamethasone on postoperative nausea and
vomiting in patients undergoing laparoscopically assisted vaginal hysterectomy.
Ambulatory Anesthesiology, 106(5), 1402-1406.
A) Are the results of the trial valid?
YES
CAN’T
NO
TELL
1. Did the trial address a clearly focused
issue?
2. Was the assignment of patients to
treatments randomized?
3. Were all of the patients who entered the
trial properly accounted for at its
conclusion?
4. Were patients, health workers and study
personnel “blind” to treatment?
5. Were the groups similar at the start of
the trial?
6. Aside from the experimental
intervention, were the groups treated
equally?

X
X
X

X
X
X

B) What are the results?
7. How large was the treatment effect?

Not discussed.

8. How precise was the estimate of the
treatment effect?

Not discussed.

C) Will the results help locally?
9. Can the results be applied in your
context?
(or to the local population?)
10. Were all clinically important outcomes
considered?
11. Are the benefits worth the harms and
costs?

YES
X

X
X

CAN’T
TELL

NO
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Critical Appraisal Skills Programme (CASP) Randomized Control Trials Checklist
E-3: Feng, P., Chu, K., Lu, I., Shieh, J., Tzeng, J., Ho, S., … Chu, C. (2009).
Haloperidol plus ondansetron prevents postoperative nausea and vomiting in patients
undergoing laparoscopic cholecystectomy. Acta Anaesthesiol Taiwan, 47(1), 3-9.
A) Are the results of the trial valid?
YES
CAN’T
NO
TELL
1. Did the trial address a clearly focused
issue?
2. Was the assignment of patients to
treatments randomized?
3. Were all of the patients who entered the
trial properly accounted for at its
conclusion?
4. Were patients, health workers and study
personnel “blind” to treatment?
5. Were the groups similar at the start of
the trial?
6. Aside from the experimental
intervention, were the groups treated
equally?

X
X
X

X
X
X

B) What are the results?
7. How large was the treatment effect?

Not discussed.

8. How precise was the estimate of the
treatment effect?

Not discussed.

C) Will the results help locally?
9. Can the results be applied in your
context?
(or to the local population?)
10. Were all clinically important outcomes
considered?
11. Are the benefits worth the harms and
costs?

YES
X

X
X

CAN’T
TELL

NO
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Critical Appraisal Skills Programme (CASP) Randomized Control Trials Checklist
E-4: Joo, J., Park, Y., Baek, J., & Moon, Y. (2015). Haloperidol dose combined with
dexamethasone for ponv prophylaxis in high-risk patients undergoing a gynecological
laparoscopic surgery: a prospective, randomized, double-blind, dose-response and
placebo-controlled study. BMC Anesthesiology, 15(99), 1-6.
A) Are the results of the trial valid?
YES
CAN’T
NO
TELL
1. Did the trial address a clearly focused
issue?
2. Was the assignment of patients to
treatments randomized?
3. Were all of the patients who entered the
trial properly accounted for at its
conclusion?
4. Were patients, health workers and study
personnel “blind” to treatment?
5. Were the groups similar at the start of
the trial?
6. Aside from the experimental
intervention, were the groups treated
equally?

X
X
X

X
X
X

B) What are the results?
7. How large was the treatment effect?

Not discussed.

8. How precise was the estimate of the
treatment effect?

Not discussed.

C) Will the results help locally?
9. Can the results be applied in your
context?
(or to the local population?)
10. Were all clinically important outcomes
considered?
11. Are the benefits worth the harms and
costs?

YES
X

X
X

CAN’T
TELL

NO
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Critical Appraisal Skills Programme (CASP) Randomized Control Trials Checklist
E-5: Wang, T., Liu, Y., Chu, C., Shieh, J., Tzeng, J., & Wang, J. (2008). Low-dose
haloperidol prevents post-operative nausea and vomiting after ambulatory laparoscopic
surgery. Acta Anaesthesiologica Scandinavica, 52, 280-284.
A) Are the results of the trial valid?
YES
CAN’T
NO
TELL
1. Did the trial address a clearly focused
issue?
2. Was the assignment of patients to
treatments randomized?
3. Were all of the patients who entered the
trial properly accounted for at its
conclusion?
4. Were patients, health workers and study
personnel “blind” to treatment?
5. Were the groups similar at the start of
the trial?
6. Aside from the experimental
intervention, were the groups treated
equally?

X
X
X

X
X
X

B) What are the results?
7. How large was the treatment effect?

Not discussed.

8. How precise was the estimate of the
treatment effect?

Not discussed.

C) Will the results help locally?
9. Can the results be applied in your
context?
(or to the local population?)
10. Were all clinically important outcomes
considered?
11. Are the benefits worth the harms and
costs?

YES
X

X
X

CAN’T
TELL

NO
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Appendix F
Cross-Study Results Analysis
Study number

Nausea & Vomiting

Pain Scores

Adverse Side Effects

1

There was a decrease in nausea
intensity and episodes of vomiting
in the group medicated with
haloperidol.

There was a decrease in VAS
pain scores in the group
medicated with haloperidol.

None noted in this study.

2

There was a decrease in PONV
when patients were medicated with
haloperidol, droperidol, or
dexamethasone. There was a further
decrease when they were medicated
with haloperidol and
dexamethasone together.

There was no statistical
difference between groups in
reported pain scores.

Two patients experienced the
EPS of motor restlessness.

3

There was a significant decrease in
patients medicated with
ondansetron and haloperidol
combined.
There was a decrease in PONV
when patients were medicated with
haloperidol.

There was no statistical
difference between groups in
reported pain scores.

Two patients experienced the
EPS of motor restlessness.

There was no statistical
difference between groups in
reported pain scores.

There were no EPS noted, the
haloperidol group with higher
dosing did experienced
increased sedation.

There was a decreased in PONV
when patients were medicated with
haloperidol or droperidol compared
to saline.

There was no statistical
difference between groups in
reported pain scores.

No adverse side effects
observed in this study.

4

5
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